EDIT News and Press, Editas Medicine Inc. From 05/12/25

2025-05-12 16:35:13 ET More on Editas Medicine Editas Medicine: Do The Risks Outweigh The Rewards? Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (...

Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo preclinical proof of concept to...

CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and vacated-in-part the Patent Trial and Appeal Board’s (PTABs) previous decis...

2025-05-12 10:00:00 ET Major earnings expected after the bell on Monday include: Plug Power ( PLUG ) Simon Property Group ( SPG ) 3D Systems Corporation ( DDD ) Petróleo Brasileiro S.A. - Petrobras ( PBR ) Editas Medicine ( EDIT ) Read ...

Redwire Corporation (RDW) is expected to report $-0.2 for Q1 2025 Organigram Global Inc. (OGI) is expected to report $-0.03 for Q2 2025 Inter & Co. Inc. (INTR) is expected to report $0.12 for Q1 2025 Pervasip Corp (PVSP) is expected to report for quarter end 2025-02-28 Maui La...

2025-05-11 18:48:14 ET Editas Medicine, Inc. (EDIT) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 10.70%. The average open to low on the day of earnings was -4.44%. The average open to...

2025-05-11 18:43:14 ET Editas Medicine, Inc. (EDIT) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in EDIT stock price following earnings has averaged ±3.91% , with a median of 3.00%. ...

2025-05-11 17:35:00 ET More on Editas Medicine Editas Medicine: Do The Risks Outweigh The Rewards? Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (...

2025-05-11 08:00:29 ET Another busy week for corporate earnings is ahead, with a diverse range of companies set to report results, offering insights into various sectors ranging from e-commerce and technology to retail and industrials. Investors will be keenly watching the performance o...

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via pr...